Results 161 to 170 of about 35,564,439 (374)
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
The Lancet, 2012 Stephen S. Lim, T. Vos, A. Flaxman, G. Danaei, K. Shibuya, Heather Adair-Rohani, Mohammad A. Almazroa, M. Amann, H. R. Anderson, K. Andrews, M. Aryee, C. Atkinson, L. Bacchus, A. Bahalim, K. Balakrishnan, J. Balmes, S. Barker-Collo, A. Baxter, M. Bell, J. Blore, F. Blyth, C. Bonner, G. Borges, R. Bourne, M. Boussinesq, M. Brauer, P. Brooks, N. Bruce, B. Brunekreef, C. Bryan-Hancock, C. Bucello, R. Buchbinder, F. Bull, R. Burnett, T. Byers, Bianca Calabria, J. Carapetis, Emily Carnahan, Z. Chafe, F. Charlson, Honglei Chen, J. S. Chen, A. T. Cheng, J. C. Child, A. Cohen, K. Colson, B. Cowie, Sarah C. Darby, S. Darling, A. Davis, L. Degenhardt, F. Dentener, D. Jarlais, K. Devries, M. Dherani, E. Ding, E. Dorsey, T. Driscoll, K. Edmond, Suad Eltahir Ali, Rebecca E. Engell, P. Erwin, S. Fahimi, Gail Falder, F. Farzadfar, A. Ferrari, M. Finucane, S. Flaxman, F. Fowkes, Greg Freedman, Michael K. Freeman, E. Gakidou, Santu Ghosh, E. Giovannucci, G. Gmel, Kathryn Graham, R. Grainger, B. Grant, D. Gunnell, H. Gutierrez, Wayne Hall, H. Hoek, A. Hogan, H. Hosgood, D. Hoy, Howard Hu, B. Hubbell, S. Hutchings, Sydney E. Ibeanusi, G. Jacklyn, Rashmi Jasrasaria, J. Jonas, H. Kan, J. Kanis, N. Kassebaum, N. Kawakami, Y. Khang, S. Khatibzadeh, J. Khoo, Cindy Kok, F. Laden, R. Lalloo, Q. Lan, T. Lathlean, J. Leasher, J. Leigh, Yang Li, J. Lin, S. Lipshultz, S. London, R. Lozano, Yuan Lu, J. Mak, R. Malekzadeh, Leslie Mallinger, W. Marcenes, L. March, Robert G. Marks, R. Martin, P. Mcgale, J. Mcgrath, S. Mehta, Z. Memish, G. Mensah, T. Merriman, R. Micha, C. Michaud, V. Mishra, Khayriyyah Mohd Hanafiah, A. Mokdad, L. Morawska, D. Mozaffarian, Tasha B. Murphy, M. Naghavi, B. Neal, P. Nelson, J. Nolla, Rosana E Norman, Casey Olives, S. Omer, J. Orchard, R. Osborne, B. Ostro, A. Page, K. Pandey, C. Parry, E. Passmore, Jayadeep Patra, N. Pearce, P. Pelizzari, M. Petzold, M. Phillips, D. Pope, C. Pope, J. Powles, M. Rao, H. Razavi, E. Rehfuess, J. Rehm, B. Ritz, F. Rivara, Thomas J Roberts, Carolyn Robinson, J. A. Rodriguez-Portales, I. Romieu, R. Room, Lisa C Rosenfeld, Ananya Roy, L. Rushton, J. Salomon, Uchechukwu Sampson, L. Sànchez-Riera, Ella Sanman, A. Sapkota, S. Seedat, P. Shi, K. Shield, R. Shivakoti, Gitanjali M Singh, D. Sleet, Emma Smith, Kirk R. Smith, Nicolas J. C. Stapelberg, K. Steenland, H. Stöckl, L. Stovner, K. Straif, L. Straney, G. Thurston, Jimmy H. Tran, R. Dingenen, A. Donkelaar, J. Veerman, L. Vijayakumar, Robert Weintraub, M. Weissman, Richard A. White, H. Whiteford, S. Wiersma, J. Wilkinson, H. Williams, Warwick Williams, N. Wilson, A. Woolf, P. Yip, J. Zielinski, Alan D. Lopez, C. Murray, M. Ezzati +208 moresemanticscholar +1 more sourceCirculating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume +13 morewiley +1 more sourceCirculating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo +6 morewiley +1 more sourceA comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately +11 morewiley +1 more sourceCell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology, EarlyView.Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos +6 morewiley +1 more source
